Answers are grounded in this paper and cite their sources.
Systematic review shows KRAS-G12C inhibitors combined with anti-EGFR therapy may improve outcomes in metastatic colorectal cancer, suggesting a shift in treatment strategies.
Initial results of KRAS-G12C inhibitors appear highly promising when they are combined with anti-EGFR therapy compared to historical therapeutic agents indicated for patients with chemotherapy-refractory CRC. Encouraging benefits warrant frontline trials with these novel therapeutics.
No takes yet. Share an insight, caveat, or question.
Boby et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: